autoimmune pulmonary alveolar proteinosis
Conditions
Interventions
whole lung lavage (WLL) treatment
Sponsors
Tokyo Medical University Hachioji Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: aPAP diagnosed according to standard diagnostic criteria with positive results of anti-GM-CSF antibody
Exclusion criteria
Exclusion criteria: 1. Diagnosed as secondary or hereditary pulmonary alveolar proteinosis 2. History of malignant disease within recent 5 years 3. Complication of cardiovascular diseases including congestive heart failure, angina pectoris, hemorrhagic tendency, etc with severe condition 4. Complication of respiratory diseases such as pulmonary infectious disease, bronchial asthma, lung fibrosis, interstitial pneumonitis, or bronchiectasis 5. History or complication of infectious diseases which require systemic administration of antibiotics, antifungal or antiviral agents within recent 2 weeks 6. Severe liver dysfunction 7. Severe renal dysfunction 8. Other patients judged to be inappropriate for the study by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The measurement of the FeNO concentration before and after the each lung lavage in the PAP patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| The comparison of the FeNO concentration with other paramters before and after the each lung lavage in the PAP patients. | — |
Countries
Japan
Contacts
Public ContactShinji Teramoto
Tokyo Medical University Hachioji Medical Center Department of Respiratory Medicine
Outcome results
None listed